Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial
Phase 1
- Conditions
- novel coronavirus pneumonia (COVID-19)
- Registration Number
- ITMCTR2000002962
- Lead Sponsor
- 1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);
2. virus turned negative after treatment;
3. Patients diagnosed with pulmonary fibrosis;
4. aged 18-70 years old;
5. patients with clear consciousness;
6. Signing the informed consent form.
Exclusion Criteria
1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease;
2. Pregnant or lactating women;
3. Patients who have mental confusion, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months, or who have other conditions not suitable for clinical study.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;
- Secondary Outcome Measures
Name Time Method 6-minute walk test, 6MWT;